I am a
Home I AM A Search Login

Papers of the Week


J Pediatr Pharmacol Ther



Evaluation of the Safety of Ketorolac in Postsurgical Infants Less Than Six Months of Age.


McElroy NA, Bustin A, Gattoline S
J Pediatr Pharmacol Ther. 2022; 27(4):347-351.
PMID: 35558356.


Ketorolac-related adverse events are not yet elucidated in neonates and infants given paucity of data. The objective of this research is to determine the incidence of major bleed in postsurgical neonates and infants treated with ketorolac, and to describe characteristics of ketorolac therapy and its effect on renal function.